<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We have developed a <z:mp ids='MP_0003815'>nude</z:mp> mouse model in which <z:mp ids='MP_0010537'>tumor regression</z:mp> is reproducibly induced by coinjection with or intratumor inoculation of EBV-immortalized B cells </plain></SENT>
<SENT sid="1" pm="."><plain>A wide spectrum of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-derived human cell lines can be established as subcutaneous <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> in sublethally irradiated athymic mice </plain></SENT>
<SENT sid="2" pm="."><plain>Most of these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> are induced to regress by human B cells immortalized with EBV </plain></SENT>
<SENT sid="3" pm="."><plain>The <z:mp ids='MP_0010537'>tumor regression</z:mp> process is characterized by superficial <z:mp ids='MP_0001651'>necrosis</z:mp> and <z:hpo ids='HP_0100699'>scarring</z:hpo> that progressively extends itself to involve <z:hpo ids='HP_0000001'>all</z:hpo> or most of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Microscopically, <z:mp ids='MP_0010537'>tumor regression</z:mp> is characterized by <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissue <z:mp ids='MP_0001651'>necrosis</z:mp>, evidence of vascular damage with intimal thickening and capillary <z:mp ids='MP_0005048'>thrombosis</z:mp>, and macrophage, but not lymphocyte or neutrophil, infiltration </plain></SENT>
<SENT sid="5" pm="."><plain>Profiles of cytokine expression differed between progressive and regressive <z:e sem="disease" ids="C0006413" disease_type="Neoplastic Process" abbrv="BL">Burkitt's tumors</z:e> in that regressive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> expressed larger levels of TNF-alpha, IL-6, IFN-gamma, IP-10, Mig, and IL-12 p35, but not other chemokines/cytokines </plain></SENT>
<SENT sid="6" pm="."><plain>IP-10 and IL-12 were found to act as potent inhibitors of <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> in vivo </plain></SENT>
<SENT sid="7" pm="."><plain>IL-12 is an inducer of IFN-gamma and indirectly of IP-10, an IFN-gamma-inducible protein, raising the possibility that the antiangiogenic effect of IL-12 is mediated by IP-10 </plain></SENT>
<SENT sid="8" pm="."><plain>Previous studies have demonstrated that IL-12 has potent antitumor activity in vivo </plain></SENT>
<SENT sid="9" pm="."><plain>Much of this activity was dependent on the presence of IFN-gamma and of immune T cells </plain></SENT>
<SENT sid="10" pm="."><plain>The observation, made in our studies, that IP-10 is an inhibitor of <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> raises the possibility that IP-10 might contribute to the antitumor effects of IL-12 by inhibiting <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> </plain></SENT>
<SENT sid="11" pm="."><plain>Inhibition of <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> by IP-10 and IL-12 is T-cell independent, suggesting that IL-12 targets at least two compartments, T cells and capillaries, each capable of mediating antitumor effects </plain></SENT>
</text></document>